Reference
Vosoughi E, et al. Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study. Journal of Clinical Oncology 41 (Suppl. 16): e13035, Jun 2023. Available from: URL: https://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13035 [abstract]
Rights and permissions
About this article
Cite this article
Capecitabine/Trastuzumab/Tucatinib. Reactions Weekly 1988, 39 (2023). https://doi.org/10.1007/s40278-023-52017-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-52017-y